European Regulators Approve Sanofi Meningitis Vaccine for Infants as Young as Six Weeks
Paris, Tuesday, 4 August 2026.
The European Commission expanded approval for Sanofi’s MenQuadfi vaccine to six-week-old infants, broadening early protection against a rapid, severe disease carrying a mortality rate up to 15 percent.
Regulatory Approval and Market Expansion
On Tuesday, August 4, 2026, European Union regulatory authorities granted approval to French pharmaceutical giant Sanofi (SNY) for the expanded use of its meningococcal vaccine MenQuadfi in infants as young as six weeks old [1]. This decision widens Sanofi’s addressable pediatric market across Europe, strengthening its competitive positioning in the global vaccines sector against rival healthcare leaders while addressing early-stage invasive meningococcal disease risks [1]. The European Commission (EC) approved an extension for Sanofi’s MenQuadfi vaccine, covering infants starting at six weeks of age against invasive meningococcal disease serogroups A, C, W, and Y [1].
Clinical Development and Regulatory Timeline
MenQuadfi was previously authorized in the EU only for individuals aged 12 months and older prior to this expansion [1]. The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on June 25, 2026, paving the way for the final Commission decision [1]. The MET58 pivotal clinical study, which supported the EU approval, evaluated the vaccine in infants from six weeks of age across 11 countries and involved more than 6,000 infants [1].
Public Health Implications and Disease Severity
Invasive meningococcal disease has a case fatality rate of 10–15% despite treatment, with up to 20% of survivors suffering permanent complications like limb amputation, hearing loss, or neurological damage [1]. Progression of the disease can occur within 24 hours, highlighting the urgency of early protection [1]. Federico Martinon-Torres, Pediatrician and Clinical Researcher at Hospital Clínico Universitario de Santiago in Spain, noted that meningococcal disease moves fast and strikes the hardest in younger children [1].
Dosing Regimens and Corporate Strategy
Approved dosing regimens include a 2+1 schedule with 0.5mL doses with at least two months interval, plus a booster in the second year of life from 12 months [1]. Alternatively, a 3+1 schedule is available for increased risk infants, with a primary series at two, four, and six months, plus a booster from 12 months [1]. Bogdana Coudsy, Global Head of Medical, Vaccines at Sanofi, stated that offering protection for the EU’s youngest children is at the heart of the company’s commitment [1].